1Yoshikawa M, Tsujii T, Matsumura K, et al. Immunosuppressive effects of ursodeoxycholic acid an immune responses. Hepatology, 1992,16: 358-364.
2Hirano F, Tanaka H, Makino Y, et al. Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class Ⅰ gene expression. J Gastroenterol, 1996,31: 55-60.
5Neuberger J. Primary biliary cirrhosis. Lancent,1997,350:875 -879.
6Heathcote EJ Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology, 2000, 31 ; 1005 - 1013.
7Mackay IR, Gershwin ME. The nature of autommune disease. Semin Liver Dis, 1997,17:3.
8Kitaeh, Hexs, Gershwin ME. Autoimmunity and environmental factors in the pathogenesis of primary of primary biliary cirrhosis. Ann med, 2004,36 ( 1 ) : 72 - 80.
9Selmi C, Znvemizzi P, Znin M, et al. Genetics and geoepidemiology of pimary biliary cirrhosis:following the fovtpints to disease etiology, Semin Liver Dis, 2005, (3) : 265 - 80.
10Gilroy Rk, Lynch SV, Strong Rw, et al. Confirmation of the role of the Mayo risk score as a predictor of resource utilization after orthotopie liver transplantation for pimary biliary cirrhosis. Liver Transpl, 2000,6: 749 - 752.
